Observational Study

Matrix metalloproteinase-2 gene polymorphisms are associated with ischemic stroke in a Hainan population

Fanglin Niu, MSa, Boping Wei, PhDb, Mengdan Yan, MSa, Jing Li, MSa, Yongri Ouyang, MSa, Tianbo Jin, PhDa,∗

Abstract
Ischemic stroke is a complex vascular disease, which has become 1 of the major causes of morbidity and mortality worldwide. More and more data showed that matrix metalloproteinases (MMPs), in particular, MMP-2 are deleterious after ischaemic stroke. This study investigated the relationship between MMP-2 and stroke risk in the Southern Chinese population.

We evaluated single nucleotide polymorphisms (SNP) of MMP-2 in stroke patients in an association study using a case-control design. Six SNPs of MMP2 were selected and genotyped by Agena MassARRAY. SNPStats, Haplovie was used to analyze genetic data. Two SNPs in the MMP-2 gene were significantly associated with stroke risk. For rs1132896 (C versus G allele), the C allele was significantly reduced stroke risk (OR = 0.56, 95% confidence intervals [95% CI] = 0.39–0.81, P = .002). The effect of the T allele of rs243849 was IS risk according to an additive genetic model (OR = 0.67, 95% CI = 0.47–0.96, P = .028). We did not find any strong linkage between the six SNPs (rs1132896, rs1053603, rs243849, rs243847, rs243832, rs7201).

The results presented strongly indicate that MMP-2 genetic variants are an important mediator of stroke risk.

Abbreviations: 95% CI = 95% confidence intervals, HW = Hardy–Weinberg equilibrium, IS = Ischemic stroke, LD = linkage disequilibrium, MMPs = matrix metalloproteinases, ORs = odds ratios, SNP = single nucleotide polymorphism.

Keywords: case-control study, Hainan population, ischemic stroke, MMP

1. Introduction
Ischemic stroke (IS) is a complex vascular disease, which has become 1 of the major causes of morbidity and mortality worldwide.[1,2] The etiology of IS is not clear, and the process of IS is the result of multiple environmental factors, such as hypertension, diabetes, hyperlipidemia, atrial fibrillation, asymptomatic carotid stenosis, drinking and smoking.[2]

However, clinical, environmental, and demographic risk factors do not fully explain disparities in IS disease progression.[3] As with many other diseases, it is the interaction between individual gene composition and environmental exposure.[4] Not all of the individuals who exposed to similar environmental factors would suffer from IS, suggesting that genetic factors play a major role in susceptibility to IS. Currently, some studies reveal that stroke is related to the inflammatory response.[3,4] Intuitively, it seems that inflammation mediators may play an important role in the pathogenesis of stroke.[5] The MMP is a family of more than 20 proteinases widely distributed in human tissues. They can be able to degrade almost all of the extracellular matrix proteins, and are essential for cell migration, development, healing processes, scar formation and other tissue changes.[6] Besides their functions in healing processes and matrix buildup, many data suggest that serum levels of MMP2 increase in the stroke.[6,8] There is established that MMPs increases in the human brain after stroke.[11] Experimental models of brain injury, some MMPs are unregulated after ischemia,[12,13] hemorrhage[14] and trauma.[11] Accumulating evidence that MMPs plays an important role in acute brain injury.[15] It has, therefore, become clear that genetic factors assist in the development of IS. MMP polymorphisms have been evaluated in various diseases. The studies have been found in cancer incidence,[15] coronary artery disease,[16] and glaucoma.[17] Not surprisingly, burgeoning research in MMP polymorphisms for various types of populations have been conducted in IS as well. This review will evaluate MMP polymorphisms and provide some insight into their roles in IS incidence and clinical outcome. There are studies that evaluated the association of
MMP2 gene polymorphism with susceptibility to stroke. Still, differences in the incidence, pathogenesis, and clinical outcome have long been noted when comparing IS among patients with different racial and ethnic backgrounds. The aim of this study was to assess the association between the MMP-2 gene polymorphism and risk of stroke in Chinese Han population.

2. Materials and methods

2.1. Subjects

The study participants comprised 250 unrelated patients who were admitted to the Haikou People’s Hospital. Cases were patients who had a first-event myocardial infarction (MI) or IS. Patients were diagnosed to be IS if they had rapid developing clinical signs of focal or global disturbance of cerebral function lasting more than 24 hours without apparent cause but vascular origin, and the patients were confirmed by computed tomography (CT) or Magnetic Resonance Imaging (MRI) according to the diagnostic criteria of IS from World Health Organization. Controls (n = 250) were matched for age and gender, who had no history of IS. Written informed consent was obtained from all the subjects who participated in this study, and the study protocol was approved by the Haikou People’s Hospital and Northwest University.

2.2. Genotyping

For the present study, 500 samples with relevant clinical data and a DNA sample were available. DNA was isolated from whole blood were used the GoldMag-Mini Whole Blood Genomic DNA Purification Kit (GoldMag Co. Ltd. Xi’an City, China) extracted. The primer is listed in Table 1. Six single nucleotide polymorphisms (SNPs) in MMP-2 were genotyped using the Agena iPLEX assays with allele detection by mass spectroscopy, using Sequenom MassARRAY technology (Agena Bioscience, San Diego, CA) and following the manufacturer’s protocol. In this study, we used Agena MassARRAY Assay Design 3.0 Software to design a Multiplexed SNP MassEXTEND assay. The PCR primers for each SNP are shown in Table 1. Data management and analysis were performed using the Agena Typer 4.0 Software (Agena Bioscience, San Diego, CA).

2.3. Statistical analysis

Statistical analysis was done with the variety of statistical software. Hardy–Weinberg equilibrium (HWE) was calculated using a Chi-squared test. Allele frequencies, odds ratios (ORs) and their 95% confidence intervals (95% CI) were calculated. Comparison of allele frequencies was done using contingency table with a chi-square test. To determine whether SNPs of MMP2 were associated with susceptibility to stroke, multiple logistic regression analysis while adjusting for age and gender was conducted. Multiple logistic regression models (codominant models, dominant models, recessive models and additive model) were conducted to determine the OR, 95% CI, and P value, while controlling for age and gender as covariates. Haploview version 4.2 was used to identify the linkage disequilibrium (LD) block and haplotypes.[22] The significance level for all statistical analyses was 0.05.

3. Results

This study consisted of 500 subjects, with 250 cases and 250 controls. The case group included 167 males and 83 females with the sex ratio of 2.01:1 and the mean age was 63.56 ± 9.83. The control group included 152 males and 98 females, in which the sex ratio was 1.55:1 and the mean age was 64.13 ± 10.22. The demographic and clinical characteristics of all studied subjects are summarized in Table 2. The age and gender between 2 groups had no statistically significant difference (P > .05). The prevalence of MMP2 SNPs genotype and allele frequencies in stroke patients and controls are presented in Table 3. The genotype distribution among the controls were in HWE (P > .05). For rs1132896 (C versus G allele), the C allele was significantly reduced stroke risk (OR 0.36, 95% CI = 0.39–0.81, P = .002). In Table 4, the inverse association C allele of the rs1132896 polymorphism might decrease risk of stroke. Compared with control group, the decrease was 0.57-fold for stroke patients carrying GG genotype in codominant model and 0.33-fold in dominant model. The effect of the T allele of rs243849 was IS risk according to an additive genetic model. In codominant model, CT versus CC in the rs243849 was associated with a greater reduce the risk of IS (OR = 0.56, 95% CI = 0.35–0.89, P = .042). CT/TT versus CC was decreased the IS risk in dominant model (OR = 0.57, 95% CI = 0.37–0.89, P = .012). Six SNPs were analyzed for LD and haplotypes using Haploview 4.2. There is no strong LD block was constructed among 6 SNPs.

Table 2

| Table 2 | Demographic characteristics of patients with ischemic stroke and control subjects. |
|---------|----------------------------------------------------------------------------------|
| Case   | Control   | P       |
| Gender |          |         |
| Male   | 167      | 152     | .193   |
| Female | 83       | 98      |        |
| Age    | 64.13 ± 10.98 | 48.31 ± 12.31 | .063   |

P value < .05 indicates statistical significance.

Table 1

| Table 1 | Primers used for this study. |
|---------|-------------------------------|
| SNP     | Band | Alleles A/B | Gene (s) | 1st-PCR | 2nd-PCR |
| rs243849 | 16q12.2 | C/G | MMP2 | ACGTTGATGATCTGCATCCGGCAAGGAAAGACGTCGGGCAACGCA | ACACCCAACTACACAGTA |
| rs1132896 | 16q12.2 | T/C | MMP2 | ACGTTGATGATCTGCATCCGGCAAGGAAAGACGTCGGGCAACGCA | TACCTGCAGCTGCAAGGTAC |
| rs2001 | 16q12.2 | T/C | MMP2 | ACGTTGATGATCTGCATCCGGCAAGGAAAGACGTCGGGCAACGCA | CCCATGTCAGCATAGTCAC |
| rs1053605 | 16q12.2 | T/C | MMP2 | ACGTTGATGATCTGCATCCGGCAAGGAAAGACGTCGGGCAACGCA | TACCTGCAGCTGCAAGGTAC |
| rs243849 | 16q12.2 | C/A | MMP2 | ACGTTGATGATCTGCATCCGGCAAGGAAAGACGTCGGGCAACGCA | CCCATGTCAGCATAGTCAC |
| rs243832 | 16q12.2 | C/A | MMP2 | ACGTTGATGATCTGCATCCGGCAAGGAAAGACGTCGGGCAACGCA | TACCTGCAGCTGCAAGGTAC |

UEP-SEQ=single nucleotide primer extension.
4. Discussion
In the present study, we identified an association between genetic polymorphism in MMP2 gene and the risk of IS. The main finding is that the C allele of the rs1132896 and the T allele of rs243849 polymorphism might decrease the risk of IS.

MMPs belong to the family of zinc-binding proteolytic enzymes, which normally remodel the extracellular matrix. MMPs participate in many physiological processes, such as cell growth, proliferation, differentiation, migration, apoptosis, and cell interactions. MMPs are secreted in the form of inactive proenzymes and obtain their active form when they are cracked by extracellular proteinases. A large number of studies have verified that the genetic polymorphisms within the MMP genes that alter expression levels of the enzymes, playing a possible role in IS development. In particular, MMP-2 is an important member in MMPs family encoded by MMP-2 gene and plays a leading role in the lesion of blood-brain barriers. A number of studies have shown that MMP-2 is involved in the formation, migration, fracture collapse of atheromatous plaque, and cerebral ischemia-reperfusion, hemorrhagic transformation, and neuron apoptosis through degrading ECM, which may be closely related to the occurrence and development of stroke.

Currently, some studies reveal that MMP2 polymorphism is correlated with an elevated risk of IS, and most study focuses on the rs243865, rs243849, rs243847, rs243832, rs7201 in MMP2 gene. We found 2 SNPs (rs1132896, rs243849) were associated with IS, similar results were found in Manso et al. study that rs243849 was significantly associated with stroke outcome in a Portuguese population sample. Marc Fatar et al. research found rs7201 were associated with IS risk in Caucasian, however, our results did not find significant differences. For rs1132896, rs1053605, rs243847, rs243832 we did not find any significant results, and other study other studies have found no correlation between these SNPs and stroke risk. Further studies on these SNPs were related to obesity, high myopia, New-Onset Diabetes et al.

There were 2 limitations in our study. First, some other genetic polymorphisms may have a role in the development of ischemic stroke, but our study only investigated the association of MMP2 gene polymorphisms with the development of IS. Second, the sample size is relatively small, which may limit the statistical power to find the differences between groups. In conclusion, our study suggests that MMP2 polymorphism is correlated with an elevated risk of IS in Southern Chinese population. Further studies with larger sample size may contribute to elucidate the impact of these polymorphisms on the risk of IS.

Author contributions
Data curation: Jing Li.
Methodology: Boping Wei, Mengdan Yan.
Project administration: Tianbo Jin.
Validation: Jing Li.
Writing – original draft: Fanglin Niu.
Writing – review & editing: Boping Wei.

References

[1] Members WG, Benjamin EJ, Blaha MJ, et al. Heart disease and stroke statistics—2017 update: a report from the American heart association. Circulation 2016;130:e46–603.

[2] Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American heart association/American stroke association. Stroke 2014;45:3754–832.

[3] Howard G, Cushman M, Kissela BM, et al. Traditional risk factors as the underlying cause of racial disparities in stroke: lessons from the half-full (empty?) glass. Stroke J Cereb Circ 2011;42:3369–75.

[4] Flossmann E, Schulz UC, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 2004;35:212–27.

[5] Xu T, Zhang YH. Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies. Br J Dermatol 2012;167:1345–50.

[6] Portegies ML, Bos MJ, Hofman A, et al. Role of prestroke vascular pathology in long-term prognosis after stroke: the rotterdam study. Stroke 2016;47:80–7.

[7] Lucivero V, Prontera M, Mezzapesa DM, et al. Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke. Neuronal Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 2007;28:165–70.

[8] Galis ZS, Sukhova GK, Libby P. Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 1995;9:974–80.

[9] Du J, Jin T, Cao Y, et al. Association between genetic polymorphisms of MMP9 and the risk of steroid-induced osteonecrosis of the femoral head in the population of northern China. Medicine 2016;95:e4794–801.

[10] Romanic AM, White RF, Arleth AJ, et al. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998;29:1020–30.

[11] Clark AW, Krekoski CA, Bou SS, et al. Increased gelatinase A (MMP-2) and gelatinase-B (MMP-9) activities in human brain after focal ischaemia. Neurosci Lett 1997;238:53–6.

[12] Gasche Y, Copin JC, Sugawara T, et al. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metabol 2001;21:1393–400.

[13] Fatar M, Stroic M, Griebe M, et al. Matrix metalloproteinases in cerebrovascular diseases. J Cereb Blood Flow Metabol Off J Int Soc Cereb Blood Flow Metabol 1998;18:1163–72.

[14] Rosenberg GA, Navaratil M. Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology 1997;48:921–6.

[15] Vecil GG, Larsen PH, Corley SM, et al. Interleukin-1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo. J Neurosci Res 2000;61:212–24.

[16] Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. Gla 2005;30:329–39.

[17] Liu L, Sun J, Li G, et al. Association between MMP-12-82A/G polymorphism and cancer risk: a meta-analysis. Int J Clin Exp Med 2015;8:11896–904.

[18] Jia P, Wu N, Zhang X, et al. Association of matrix metalloproteinase-1-519A/G polymorphism with acute coronary syndrome: a meta-analysis. Int J Clin Exp Med 2015;66:6111–2.

[19] Zhang Y, Wang M, Zhang S. Association of MMP-9 gene polymorphisms with glaucoma: a meta-analysis. Ophthalmic Res 2016;53:172–9.

[20] Gabriel S, Zaugga L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Current Protocols in Human Genetics. 2009;Chapter 2(Unit 2):Unit 2.12.

[21] Bland JM, Altman DG. Statistics notes. The odds ratio. BMJ 2000;320:1686.

[22] Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:266–7.

[23] Elkington PT, O’Kane CM, Friedland JS. The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol 2005;142:1–20.

[24] Yu , Yan , Xie , et al. Single-nucleotide polymorphisms ofMMP2in MMP/TIMP pathways associated with the risk of alcohol-induced osteonecrosis of the femoral head in Chinese males: a case-control study. Medicine 2016;95:e5407–913.

[25] Machado GF, Melo GD, Souza MS, et al. Zymographic patterns of MMP-2 and MMP-9 in the CSF and cerebellum of dogs with subacute distemper leukoencephalitis. Vet Immunol Immunopathol 2013;154:68–74.

[26] Chen J, Guo Y, Jin T, et al. Association of MMPs/TIMPs polymorphism with alcohol-induced osteonecrosis of femoral head in the Chinese Han population. Int J Clin Exp Pathol 2016;9:8231–8.

[27] Nakaji K, Ibara M, Takashashi C, et al. Matrix metalloproteinase-2 plays a critical role in the pathogenesis of white matter lesions after chronic cerebral hyperperfusion in rodents. Stroke 2006;37:2816–23.

[28] Lu A, Suofu Y, Guan F, et al. Matrix metalloproteinase-2 deletions protect against hemorrhagic transformation after 1 hour of cerebral ischemia and 23 hours of reperfusion. Neuroscience 2013;253:361–7.

[29] Hill JW, Poddar R, Thompson JP, et al. Intranuclear matrix metalloproteinases promote DNA damage and apoptosis induced by oxygen-glucose deprivation in neurons. Neuroscie 2012;220:277–90.

[30] Addition I, Ax S. An inflammatory polymorphisms risk scoring system for the differentiation of ischemic stroke subtypes. Mediators Inflamm 2015;2015:569714–21.

[31] Chang JJ, Stanfill A, Pourmotabbed T. The role of matrix metalloproteinase polymorphisms in ischemic stroke. Int J Mol Sci 2016;17:1123–38.

[32] Yumluu H, Shihong T, Min S, et al. Association between matrix metalloproteinase gene polymorphisms and development of ischemic stroke. Int J Clin Exp Pathol 2015;8:11647–52.

[33] Zhang L, Ren R, Mu S. The correlation of MMP-2 polymorphisms and stroke. Int J Clin Exp Med 2016;9:4460–6.

[34] Manso H, Krug T, Sobral J, et al. Variants of the Matrix Metalloproteinase-2 but not the Matrix Metalloproteinase-9 genes significantly influence functional outcome after stroke. BMC Med Genet 2010;11:1–9.

[35] Fatar M, Stroic M, Steffens M, et al. Single-nucleotide polymorphisms of MMP-2 gene in stroke subtypes. Cerebrovasc Dis 2007;26:113–9.

[36] Han DH, Kim SK, Kang S, et al. Matrix metalloproteinases 2 gene polymorphism is associated with obesity in Korean population. Korean J Physiol Pharmacol Off J Korean Physiol Soc Korean Soc Pharmacol 2008;12:125–9.

[37] Bo G, Liu X, Zhang D, et al. Evaluation of MMP2 as a candidate gene for high myopia. Mol Vis 2013;19:121–7.

[38] Ong S, Kang SW, Kim YH, et al. Matrix metalloproteinase gene polymorphisms and new-onset diabetes after kidney transplantation in Korean renal transplant subjects. Transplant Proc 2016;48:858–63.